Results 141 to 150 of about 39,021 (326)
Precision Radiation Oncology, EarlyView.The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song +5 more
wiley +1 more source
UroPrecision, EarlyView.Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley +1 more source
Cancer Management and ResearchBin Liu,* Bingtian Zhao,* Yan Yin, Yan Jiang, Xue Feng, Lei Wang, Liang Zhai, Guangxin Liu, Dongsheng Shi, Jianwen Qin Department of Respiratory and Critical Medicine, Tianjin Chest Hospital, Tianjin, People’s Republic of China*These authors ...
Liu B +9 more
doaj
VIEW, EarlyView.Our study presents a tumour‐informed circulating tumour DNA (ctDNA) workflow designed to enhance the detection of recurrence in head and neck cancer patients, addressing key challenges such as low ctDNA tumour fractions and tumour heterogeneity. Abstract Circulating tumour DNA (ctDNA) is a promising minimally invasive biomarker for monitoring treatment
Xiaomin Huang +8 more
wiley +1 more source
ADN tumoral circulante en pacientes con cáncer: perspectivas desde el laboratorio clínico
Advances in Laboratory MedicineEl análisis de ADN tumoral circulante (ctDNA) es un método no invasivo de gran relevancia para la caracterización molecular de los tumores sólidos, que aporta información valiosa sobre el perfil genético del cáncer. Actualmente, el análisis de mutaciones
Illana Francisco J. +13 more
doaj +1 more source
Clinical implications of ctDNA in predicting the genetic subtype, CNS involvement and outcomes of newly diagnosed diffuse large B cell lymphoma [PDF]
, 2023 Jie Liang +9 more
openalex +1 more source
Asia-Pacific Journal of Clinical Oncology, EarlyView.This study explores the current status, utilization, and barriers to circulating tumour DNA (ctDNA) testing in thoracic oncology across Australia and New Zealand. While clinicians recognize the potential of ctDNA for guiding targeted therapy and monitoring disease, real‐world access remains inconsistent due to funding, availability, and infrastructure ...
Yifei Zhu +4 more
wiley +1 more source
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions
, 2021 Sebastián Mondaca +33 more
openalex +2 more sources
Asia-Pacific Journal of Clinical Oncology, EarlyView.We selected breast cancer‐specific DNA methylation markers using The Cancer Genome Atlas (TCGA). We analyzed the methylation and expression patterns of candidate genes in breast cancer cell lines, ctDNA, and tissue samples. The relationship between ctDNA methylation markers and the clinicopathological features of breast cancer patients was investigated.
Young Ju Jeong +6 more
wiley +1 more source
Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B‐cell lymphoma patients
British Journal of Haematology, EarlyView.Summary The response to salvage chemotherapy in relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) is poor, and data on circulating tumour deoxyribonucleic acid (ctDNA) in this setting are limited. We evaluated ctDNA dynamics in 29 patients with relapsed or refractory DLBCL who received platinum‐based salvage chemotherapy at the University
Yujie Zhong +9 more
wiley +1 more source